? CAREER DEVELOPMENT PROGRAM The Developmental Hyperactive Ras Tumor (DHART) SPORE Career Development Program (CDP) will support faculty at the Assistant Professor level to engage in translational research focused on NF1 and cancer. The specific purpose or the CDP is to advance the careers of junior investigators who are developing innovative research projects related to the goal of implementing more effective and less toxic therapies for cancers characterized by NF1 mutations. The DHART SPORE also includes a Developmental Research Program (DRP), which has the complementary mission of funding established investigators who seek to develop new research related to NF1-related cancers and is presented in a separate section of this application. The multi-institutional nature of this SPORE leverages a large and talented pool of junior faculty from multiple disciplines. Each institution views the CDP as a vehicle for recruiting, training, and advancing young scientists working in the area of translational cancer research related to NF1, and they have committed $1.3 million to support the Developmental Programs component of the DHART SPORE (DRP and CDP).
The Specific Aims of the CDP are: (1) to support new investigators as they develop innovative research programs with the goal of contributing new knowledge to the field of NF1-related cancer research while generating preliminary data that will allow them to successfully apply for independent extramural funding; (2) to provide young researchers with didactic training that will equip them with essential skills and knowledge for success as an independent investigator in the field of NF1-related cancer research; (3) to mentor young translational researchers through regularly scheduled one-on-one meetings with a designated senior faculty member and a structured Individual Career Development Plan (IDP) who will fully integrate the CDP-supported investigator into the fabric of the DHART SPORE where they have access to advice, resources, and potential collaborators; and, (4) to encourage the recruitment of ethnic minorities, those from disadvantaged backgrounds, women and lesbian/gay/bisexual/transgender (LGBT) populations into research focused on NF1-associated cancers. The DHART SPORE will link vertically and horizontally to diversity programs at all of the consortium institutions. Investigators from any of these centers can apply for CDP funds, and we will also consider proposals from researchers at other institutions. The CDP will fund a minimum of two projects per year at an annual budget of $50,000 - $75,000. Applications for CDP support (including requests for a second year of funding) will be evaluated through a competitive process with review by a Developmental Programs Steering Committee comprised on senor scientists participating in this SPORE and oversight and guidance from the External and Internal Advisory Boards.

Public Health Relevance

? CAREER DEVELOPMENT PROGRAM The Developmental Hyperactive Ras Tumor (DHART) SPORE Career Development Program (CDP) will support and mentor faculty at the Assistant Professor level to engage in translational research focused on developing better treatments for tumors characterized by mutations in the NF1 gene. The CDP will identify and recruit these young investigators, who will benefit from advice, interactions within the SPORE, and core expertise and facilities to accelerate their career development as independent researchers in the field of cancer biology and therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA196519-01
Application #
8932167
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2015-09-01
Project End
2020-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$104,458
Indirect Cost
$10,253
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Brosseau, Jean-Philippe; Liao, Chung-Ping; Wang, Yong et al. (2018) NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat Commun 9:5014
Liao, Chung-Ping; Booker, Reid C; Brosseau, Jean-Philippe et al. (2018) Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest 128:2848-2861
Lu, Jia; Bera, Asim K; Gondi, Sudershan et al. (2018) KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry 57:324-333
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Yoshimi, Akihide; Balasis, Maria E; Vedder, Alexis et al. (2017) Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood 130:397-407
Strowd 3rd, Roy E; Blakeley, Jaishri O (2017) Common Histologically Benign Tumors of the Brain. Continuum (Minneap Minn) 23:1680-1708
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Sherborne, Amy L; Lavergne, Vincent; Yu, Katharine et al. (2017) Somatic and GermlineTP53Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clin Cancer Res 23:1852-1861
Davidson, Philip R; Sherborne, Amy L; Taylor, Barry et al. (2017) A pooled mutational analysis identifies ionizing radiation-associated mutational signatures conserved between mouse and human malignancies. Sci Rep 7:7645

Showing the most recent 10 out of 12 publications